Dual role of glutathione in modulating camptothecin activity: Depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex

Molecular Cancer Therapeutics

Volumn 1, Issue 1, 2001, Pages 11-20

  Gamcsik, Michael P ^a   Kasibhatla, Mohit S ^a   Adams, David J ^a   Flowers, James L ^a   Colvin, O Michael ^a   Manikumar, Govindarajan ^b   Wani, Mansukh ^b   Wall, Monroe E ^b   Kohlhagen, Glenda ^c   Pommier, Yves ^c  

^a DUKE CANCER INSTITUTE   (United States)

^b RTI INTERNATIONAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUTHIONINE SULFOXIMINE; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; DRUG DERIVATIVE; GLUTATHIONE;

ARTICLE; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BUTHIONINE SULFOXIMINE; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG SYNERGISM; FEMALE; GLUTATHIONE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0035523958     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hsiang, Y. H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989. (Pubitemid 19239347)
2. Pommier, Y., Pourquier, P., Fan, Y., and Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400: 83-105, 1998.
3. Pommier, Y., Pourquier, P., Urasaki, Y., Wu, J., and Laco, G. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Updat., 2: 307-318, 1999. (Pubitemid 30070455)
4. Adams, D. J., Dewhirst, M. W., Flowers, J. L., Gamcsik, M. P., Colvin, O. M., Manikumar, G., Wani, M. C., and Wall, M. E. Camptothecin analogues with enhanced antitumor activity at acidic pH. Cancer Chemother. Pharmacol., 46: 263-271, 2000.
5. Pommier, Y., Kohlhagen, G., Kohn, K. W., Leteurtre, F., Wani, M. C., and Wall, M. E. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sci. USA, 92: 8861-8865, 1995.
6. Valenti, M., Nieves-Neira, W., Kohlhagen, G., Kohn, K. W., Wall, M. E., Wani, M., and Pommier, Y. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol. Pharmacol., 52: 82-87, 1997. (Pubitemid 27318622)
7. Colvin, O. M., Friedman, H. S., Gamcsik, M. P., Fenselau, C., and Hilton, J. Role of glutathione in cellular resistance to alkylating agents. Adv. Enzyme Regul., 33: 19-26, 1993. (Pubitemid 223051907)
8. Matsumoto, Y., Fujiwara, T., and Nagao, S. Determinants of drug response in camptothecin-11 resistant cell lines. J. Neurooncol., 23: 1-8, 1995.
9. Niimi, S., Nakagawa, K., Sugimoto, Y., Nishio, K., Fujiwara, Y., Yokoyama, S., Terashima, Y., and Saijo, N. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res., 52: 328-333, 1992.
10. Sawyer, T. E., and Bonner, J. A. The interaction of buthionine sulphoximine (BSO) and the topoisomerase I inhibitor CPT-11. Br. J. Cancer, 74 (Suppl.): S109-S113, 1996. (Pubitemid 26237941)
11. Zhelkovsky, A. M., and Moore, C. L. Overexpression of human DNA topoisomerase I in insect cells using a baculovirus vector. Protein Expression Purif., 5: 364-370, 1994. (Pubitemid 2127228)
12. Luzzio, M. J., Besterman, J. M., Emerson, D. L., Evans, M. G., Lackey, K., Leitner, P. L., McIntyre, G., Morton, B., Myers, P. L., Peel, M., et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J. Med. Chem., 38: 395-401, 1995.
13. Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Tele, C., Moore, L., Truesdale, A., Leitner, P., and Besterman, J. M. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem., 36: 2689-2700, 1993. (Pubitemid 23294136)
14. Pourquier, P., Takebayashi, Y., Urasaki, Y., Gioffre, C., Kohlhagen, G., and Pommier, Y. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc. Natl. Acad. Sci. USA, 97: 1885-1890, 2000. (Pubitemid 30118538)
15. Flowers, J. L., Ludeman, S. M., Gamcsik, M. P., Colvin, O. M., Shao, K-L., Boal, J. H., Springer, J. B., and Adams, D. J. Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. Cancer Chemother. Pharmacol., 45: 335-344, 2000. (Pubitemid 30151528)
16. Millis, K. K., Lesko, S. A., and Gamcsik, M. P. Formation, intracellular distribution and efflux of glutathione-bimane conjugates in drug-sensitive and -resistant MCF-7 cells. Cancer Chemother. Pharmacol., 40: 101-111, 1997. (Pubitemid 27214587)
17. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res., 49: 5016-5022, 1989. (Pubitemid 19239335)
18. Kohn, K. W., Ewig, R. A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and crosslinks by alkaline elution. In: E. C. Friedberg and P. C. Hanawalt (eds.), DNA Repair: A Laboratory Manual of Research Procedures, pp. 379-401. New York: Marcel Dekker Inc., 1981.
19. Warner, D. L., and Burke, T. G. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J. Chromatogr. B Biomed. Sci. Appl., 691: 161-171, 1997. (Pubitemid 27168851)
20. Pommier, Y., Kohlhagen, G., Wu, C., and Simmons, D. T. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen. Biochemistry, 37: 3818-3823, 1998. (Pubitemid 28162937)
21. Pourquier, P., Ueng, L. M., Kohlhagen, G., Mazumder, A., Gupta, M., Kohn, K. W., and Pommier, Y. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem., 272: 7792-7796, 1997. (Pubitemid 27137335)
22. Strumberg, D., Pommier, Y., Paull, K., Jayaraman, M., Nagafuji, P., and Cushman, M. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J. Med. Chem., 42: 446-457, 1999. (Pubitemid 29085106)
23. Griffith, O. W. L-Buthionine-S,R-sulfoximine: mechanism of action, resolution of diastereomers and use as a chemotherapeutic agent. In: N. Taniguchi, T. Higashi, Y. Sakamoto, and A. Meister (eds.), Glutathione Centennial Molecular Perspectives and Clinical Implications, pp. 285-299. New York: Academic Press, 1989.
24. Nabiev, I., Fleury, F., Kudelina, I., Pommier, Y., Charton, F., Riou, J-F., Alix, A. J. P., and Manfait, M. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family. Their possible role in the unique mode of drug action. Biochem. Pharmacol., 55: 1163-1174, 1998. (Pubitemid 28206704)
25. Eng, W. K., McCabe, F. L., Tan, K. B., Mattern, M. R., Hofmann, G. A., Woessner, R. D., Hertzberg, R. P., and Johnson, R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol. Pharmacol., 38: 471-480, 1990. (Pubitemid 20356196)
26. Fernandes, R. S., and Cotter, T. G. Apoptosis or necrosis: intracellular levels of glutathione influence mode of cell death. Biochem. Pharmacol., 48: 675-681, 1994. (Pubitemid 24283836)
27. Hiraoka, W., Vazquez, N., Nieves-Neira, W., Chanock, S. J., and Pommier, Y. Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J. Clin. Investig., 102: 1961-1968, 1998. (Pubitemid 29001842)
28. Davis, W., Jr., Ronai, Z., and Tew, K. D. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J. Pharmacol. Exp. Ther., 296: 1-6, 2001. (Pubitemid 32015053)
29. Keppler, D., Leier, I., Jedlitschky, G., and Konig, J. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem. Biol. Interact., 111-112: 153-161, 1998. (Pubitemid 28271941)
30. Shen, H., Paul, S., Breuninger, L. M., Ciaccio, P. J., Laing, N. M., Helt, M., Tew, K. D., and Kruh, G. D. Cellular and in vitro transport of glutathione conjugates by MRP. Biochemistry, 35: 5719-5725, 1996. (Pubitemid 26143667)
31. Chu, X-Y., Kato, Y., Kiinuma, K., Sudo, K. I., Hakusui, H., and Sugiyama, Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther., 281: 304-314, 1997. (Pubitemid 27203082)
32. Chu, X-Y., Kato, Y., and Sugiyama, Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res., 57: 1934-1938, 1997. (Pubitemid 27209724)
33. Chu, X. Y., Kato, Y., and Sugiyama, Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab. Dispos., 27: 440-441, 1999. (Pubitemid 29177635)
34. Chu, X. Y., Suzuki, H., Ueda, K., Kato, Y., Akiyama, S., and Sugiyama, Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J. Pharmacol. Exp. Ther., 288: 735-741, 1999. (Pubitemid 29119689)
35. Chen, Z. S., Furukawa, T., Sumizawa, T., Ono, K., Ueda, K., Seto, K., and Akiyama, S. I. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol. Pharmacol., 55: 921-928, 1999. (Pubitemid 29214612)
36. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C., Robey, R., Pommier, Y., Fojo, T., and Bates, S. E. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res., 59: 5938-5946, 1999. (Pubitemid 30004955)
37. Pommier, Y., Gupta, M., Valenti, M., and Nieves-Neira, W. Cellular resistance to camptothecins. Ann. N. Y. Acad. Sci., 803: 60-73, 1996. (Pubitemid 27057975)
38. Hoki, Y., Fujimori, A., and Pommier, Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol., 40: 433-438, 1997. (Pubitemid 27346543)
39. Tanizawa, A., Kohn, K. W., Kohlhagen, G., Leteurtre, F., and Pommier, Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry, 43: 7200-7206, 1995.
40. Bom, D., Curran, D. P., Kruszewski, S., Zimmer, S. G., Thompson Strode, J., Kohlhagen, G., Du, W., Chavan, A. J., Fraley, K. A., Bingcang, A. L., Latus, L. J., Pommier, Y., and Burke, T. G. The novel silatecan 7-tert- butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem., 43: 3970-3980, 2000.
41. Van Hattum, A. H., Pinedo, H. M., Schluper, H. M., Hausheer, F. H., and Boven, E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int. J. Cancer, 88: 260-266, 2000.